Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide in Refractory Cutaneous Lupus
NCT01408199Phase 4Completed
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Jan 2010
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of lenalidomide in cutaneous lupus erythematosus (CLE), sponsored by Vall d'Hebron Research Institute. Started Jan 2010; status: completed.
02
Drugs
lenalidomide
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT01408199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01408199.